comscoreWhat My Patients Are Asking: What Is the Lung Inflammation Side Effect Caused by CDK4/6 Inhibitors?

What My Patients Are Asking: What Is the Lung Inflammation Side Effect Caused by CDK4/6 Inhibitors?

Brian Wojciechowski, MD, talks about the recent FDA statement on lung inflammation associated with CDK4/6 inhibitors.
Dec 20, 2019
00:00
Download
00:00

In September 2019, the U.S. Food and Drug Administration released a statement warning that the CDK4/6 inhibitors used to treat breast cancer:

  • Ibrance (chemical name: palbociclib)

  • Kisqali (chemical name: ribociclib)

  • Verzenio (chemical name: abemaciclib)

may cause rare but serious inflammation in the lungs.

Listen to the podcast to hear Dr. Wojciechowski talk about:

  • how CDK4/6 inhibitors are used to treat breast cancer

  • why we’re just hearing about this side effect now

  • he recommendations for anyone being treated with a CDK4/6 inhibitor

About the guest
 
Brian Wojciechowski headshot
Brian Wojciechowski, MD

Dr. Wojo is a medical oncologist outside of Philadelphia, PA, with Crozer Health. His research has been presented at the San Antonio Breast Cancer Symposium, and he is a speaker on medical ethics and the biology of cancer. Dr. Wojo sees cancer as a scientifically complex disease with psychological, social, and spiritual dimensions.

— Last updated on June 29, 2022, 2:46 PM

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate